Zoetis Inc. $ZTS Shares Sold by Bailard Inc.

Bailard Inc. decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 2.2% during the 2nd quarter, HoldingsChannel reports. The fund owned 64,144 shares of the company’s stock after selling 1,425 shares during the quarter. Bailard Inc.’s holdings in Zoetis were worth $10,003,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Nova Wealth Management Inc. acquired a new position in shares of Zoetis in the 1st quarter valued at approximately $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis during the first quarter worth approximately $27,000. Saudi Central Bank bought a new stake in shares of Zoetis in the first quarter worth $29,000. REAP Financial Group LLC raised its holdings in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after acquiring an additional 131 shares in the last quarter. Finally, NewSquare Capital LLC boosted its stake in Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $120.09 on Wednesday. The company has a market cap of $52.92 billion, a P/E ratio of 20.67, a PEG ratio of 2.31 and a beta of 0.90. The business has a 50 day moving average of $142.82 and a two-hundred day moving average of $152.16. Zoetis Inc. has a 52 week low of $117.26 and a 52 week high of $181.85. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter last year, the business posted $1.58 EPS. The business’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. Zoetis’s payout ratio is 33.67%.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZTS. UBS Group dropped their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Piper Sandler boosted their price objective on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Monday, August 11th. Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research note on Tuesday, September 9th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Finally, Morgan Stanley dropped their price target on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research report on Monday. Five investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Zoetis presently has a consensus rating of “Moderate Buy” and an average target price of $182.50.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.